Table 3.

 Stent thromboses in trials with dual antiplatelet therapy of six months or more

Variable	Events					Relative risks (95% credibility interval)
	BMS	PES	SES	Total		SES v BMS	PES v BMS	SES v PES
ARC definite stent thrombosis*
Patients with diabetes:
No of patients at risk	557	874	753	2184
0 days to 4 years	13	17	9	39		0.33 (0.09 to 1.09)	0.82 (0.23 to 3.09)	0.40 (0.13 to 1.08)
0-30 days	11	9	6	26		0.25 (0.04 to 1.11)	0.39 (0.05 to 2.36)	0.60 (0.12 to 3.36)
>30 days to 4 years	2	8	3	13		0.72 (0.04 to 10.8)	3.54 (0.23 to 78.6)	0.20 (0.02 to 1.04)
Patients without diabetes:
No of patients at risk	2439	3130	2647	8216
0 days to 4 years	34	56	46	136		1.24 (0.58 to 3.08)	1.48 (0.69 to 3.40)	0.84 (0.41 to 1.88)
0-30 days	19	22	28	69		1.19 (0.43 to 3.09)	1.11 (0.38 to 2.97)	1.06 (0.41 to 2.90)
>30 days to 4 years	15	34	18	67		1.19 (0.43 to 4.13)	1.83 (0.67 to 5.85)	0.65 (0.26 to 1.70)
Per protocol definition of stent thrombosis†
Patients with diabetes:
No of patients at risk	723	912	870	2505
0 days to 4 years	16	18	7	41		0.20 (0.05 to 0.68)	0.73 (0.19 to 2.80)	0.27 (0.07 to 0.80)
0-30 days	11	10	5	26		0.23 (0.03 to 1.08)	0.55 (0.09 to 3.05)	0.42 (0.07 to 1.89)
>30 days to 4 years	5	8	2	15		0.10 (0.01 to 0.93)	0.87 (0.06 to 10.3)	0.11 (0.01 to 0.75)
Patients without diabetes:
No of patients at risk	2577	3382	2625	8584
0 days to 4 years	29	58	46	133		1.48 (0.74 to 3.41)	1.80 (0.89 to 3.67)	0.82 (0.44 to 1.73)
0-30 days	22	24	28	74		1.11 (0.47 to 2.81)	0.99 (0.44 to 2.33)	1.15 (0.48 to 2.72)
>30 days to 4 years	7	34	18	59		2.29 (0.83 to 7.77)	4.12 (1.55 to 13.1)	0.55 (0.25 to 1.27)

BMS=bare metal stent; PES=paclitaxel eluting stent; SES=sirolimus eluting stent.

*According to Academic Research Consortium criteria.

†According to protocol definitions used in individual trials.